News/ News/ Oncology BMS signs $475m cancer immunotherapy deal with Dragonfly Richard Staines Bristol-Myers Squibb, cancer, Dragonfly, Oncology, Ziopharm 0 Comment Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug Share X BMS signs $475m cancer immunotherapy deal with Dragonfly https://pharmaphorum.com/news/bms-signs-475m-deal-to-develop-cancer-immunotherapy-with-dragonfly/
Bristol-Myers Squibb, cancer, Dragonfly, Oncology, Ziopharm
0 Comment
